Identification of 15 T Cell Restricted Genes Evaluates T Cell Infiltration of Human Healthy Tissues and Cancers and Shows Prognostic and Predictive Potential
暂无分享,去创建一个
[1] V. Chan,et al. Pathogenic role of tissue-resident memory T cells in autoimmune diseases. , 2018, Autoimmunity reviews.
[2] B. Rini,et al. Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma , 2018, Medicine.
[3] Kongming Wu,et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular Cancer.
[4] J. Grob,et al. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives , 2018, Drugs.
[5] R. V. van Lier,et al. Tissue-resident memory T cells at the center of immunity to solid tumors , 2018, Nature Immunology.
[6] D. Tscharke,et al. Tissue‐resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance , 2018, Immunological reviews.
[7] K. Kabashima,et al. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..
[8] L. Garraway,et al. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas , 2018, Oncoimmunology.
[9] C. Riccardi,et al. Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis , 2018, Oncoimmunology.
[10] Javier Martín,et al. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape , 2017, Oncotarget.
[11] C. Criscitiello,et al. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. , 2017, Breast.
[12] Yufeng Shen,et al. Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. , 2017, Cell reports.
[13] Carsten Denkert,et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe , 2017, Advances in anatomic pathology.
[14] A. Butte,et al. xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.
[15] A. Kallies,et al. Transcriptional Regulation of Tissue-Resident Lymphocytes. , 2017, Trends in immunology.
[16] R. Sackstein,et al. T-Lymphocyte Homing: An Underappreciated yet Critical Hurdle for Successful Cancer Immunotherapy , 2017, Laboratory investigation; a journal of technical methods and pathology.
[17] J. Sosman,et al. Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065)) , 2017 .
[18] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[19] C. Paweletz,et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. , 2016, JCI insight.
[20] W. Cooper,et al. The Role of Tumor‐Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] Pornpimol Charoentong,et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.
[22] P. Hegde,et al. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.
[23] A. Rudensky,et al. Hallmarks of Tissue-Resident Lymphocytes , 2016, Cell.
[24] R. Gibbs,et al. Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.
[25] C. Riccardi,et al. Modulation of tumor immunity: a patent evaluation of WO2015026684A1 , 2016, Expert opinion on therapeutic patents.
[26] C. Meijer,et al. Extent and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant active specific immunotherapy , 2015, Journal of Immunotherapy for Cancer.
[27] Antoni Ribas,et al. Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.
[28] Cesare Furlanello,et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma , 2015, Oncoimmunology.
[29] Pornpimol Charoentong,et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.
[30] G. Brodeur,et al. Mechanisms of neuroblastoma regression , 2014, Nature Reviews Clinical Oncology.
[31] Robert Petryszak,et al. ArrayExpress update—simplifying data submissions , 2014, Nucleic Acids Res..
[32] Roland Eils,et al. Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers , 2014, Clinical Cancer Research.
[33] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[34] Zhandong Liu,et al. Digital sorting of complex tissues for cell type-specific gene expression profiles , 2013, BMC Bioinformatics.
[35] R. Seeger. Immunology and immunotherapy of neuroblastoma. , 2011, Seminars in cancer biology.
[36] J. Maris. Recent advances in neuroblastoma. , 2010, The New England journal of medicine.
[37] Peter Widmayer,et al. Genevestigator V3: A Reference Expression Database for the Meta-Analysis of Transcriptomes , 2008, Adv. Bioinformatics.
[38] L. Zitvogel,et al. The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.
[39] M. Koch,et al. Tumor Infiltrating T Lymphocytes in Colorectal Cancer: Tumor-Selective Activation and Cytotoxic Activity In Situ , 2006, Annals of surgery.
[40] I. Lauder,et al. The Significance of Lymphocytic Infiltration in Neuroblastoma , 1972, British Journal of Cancer.
[41] Ash A. Alizadeh,et al. SUPPLEMENTARY NOTE , 1879, Botanical Gazette.
[42] Masato Takahashi,et al. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) , 2017, Breast Cancer.
[43] T. Nielsen,et al. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication , 2016, Breast Cancer.
[44] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..